Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
MOBI Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Mobia Medical, Inc. Common Stock
Market Cap
$292.59M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$293.30M
Return on Equity (ROE)
-135.62%
TTM Avg
-521.17%
3Y Avg
-307.05%
5Y Avg
43.03%
Market Cap
$288.79M
Return on Equity (ROE)
-135.50%
TTM Avg
-129.54%
3Y Avg
-84.04%
5Y Avg
-77.00%
Market Cap
$285.55M
Return on Equity (ROE)
-49.11%
TTM Avg
-50.02%
3Y Avg
-153.47%
5Y Avg
-149.41%
Market Cap
$285.42M
Return on Equity (ROE)
-18.38%
TTM Avg
-37.53%
3Y Avg
-22.34%
5Y Avg
-10.93%
Market Cap
$284.31M
Return on Equity (ROE)
-21.41%
TTM Avg
-11.72%
3Y Avg
-50.56%
5Y Avg
-98.46%
Market Cap
$282.64M
Return on Equity (ROE)
-16.18%
TTM Avg
-23.55%
3Y Avg
59.17%
5Y Avg
22.66%
Market Cap
$281.54M
Return on Equity (ROE)
-27.36%
TTM Avg
-12.73%
3Y Avg
-30.52%
5Y Avg
-39.12%
Market Cap
$280.37M
Return on Equity (ROE)
-56.36%
TTM Avg
-35.98%
3Y Avg
25430.43%
5Y Avg
20391.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $292.59M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $293.30M | -135.62% | -521.17% | -307.05% | 43.03% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | -135.50% | -129.54% | -84.04% | -77.00% |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | -49.11% | -50.02% | -153.47% | -149.41% |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.42M | -18.38% | -37.53% | -22.34% | -10.93% |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | -21.41% | -11.72% | -50.56% | -98.46% |
| Standard BioTools Inc. (LAB)vs › | $282.64M | -16.18% | -23.55% | 59.17% | 22.66% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | -27.36% | -12.73% | -30.52% | -39.12% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | -56.36% | -35.98% | 25430.43% | 20391.58% |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | -25.73% | -32.35% | -2448.72% | -1749.34% |
ROE
N/A
ROA
-96.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 30.84% |
